SCHEMBL29924072

SCHEMBL29924072

CCCCOC(=O)N1CCC(CC=O)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.54
POLB P06746 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
GAA P10253 1/20 0.42
ATM Q13315 2/20 0.39
THRB P10828 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HRH2 P25021 1/20 0.39
HRH1 P35367 1/20 0.39
CHRM1 P11229 2/20 0.39
CHRM2 P08172 1/20 0.39
MMP13 P45452 2/20 0.38
NOS3 P29474 1/20 0.38
NOS2 P35228 1/20 0.38
MMP2 P08253 1/20 0.38
MMP3 P08254 1/20 0.38
MMP9 P14780 1/20 0.38
MMP8 P22894 1/20 0.38
HPGD P15428 2/20 0.37
ALDH1A1 P00352 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9198547 0.86 GAA (0.56) POLBSMN1; SMN2GAAATMTHRB
SCHEMBL30711555 0.85 LMNA (0.49) LMNAPOLBSMN1; SMN2ATMHRH2
SCHEMBL11974037 0.83 POLB (0.58) LMNAPOLBSMN1; SMN2GAAATM
SCHEMBL725320 0.83 LMNA (0.58) LMNAPOLBSMN1; SMN2GAAATM
SCHEMBL16256877 0.83 LMNA (0.58) LMNAPOLBSMN1; SMN2GAAATM
SCHEMBL7010085 0.82 SMN1; SMN2 (0.54) LMNAPOLBSMN1; SMN2GAAATM
SCHEMBL4204342 0.82 LMNA (0.54) LMNAPOLBSMN1; SMN2GAAATM
SCHEMBL5500990 0.82 LMNA (0.56) LMNAPOLBSMN1; SMN2GAAATM
SCHEMBL726694 0.82 SMN1; SMN2 (0.56) LMNAPOLBSMN1; SMN2GAAATM
SCHEMBL7985579 0.82 LMNA (0.56) LMNAPOLBSMN1; SMN2GAAATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220289752-A1 IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES USED AS TLR8 AGONISTS BEONE MEDICINES I GMBH (CH) 2022-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289752-A1 IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES USED AS TLR8 AGONISTS TLR8, TLR1, TLR7 LMNA 3906/4885POLB 3044/4885SMN1; SMN2 1944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.